When immunotherapy stops working for advanced stomach or colon cancer, patients often have few options left. This small, early-stage study tested a new idea: what if we could 'reset' a patient's gut bacteria to help their immune system fight back? Ten patients whose cancers had become resistant to standard immunotherapy received a transplant of healthy donor gut bacteria, taken in capsule form, alongside continued immunotherapy treatment. The most important finding was that this combination was safe, with no serious side effects reported. In terms of early results, two out of the ten patients (20%) saw their tumors shrink, and four patients (40%) had their disease stop growing for a period. The researchers saw that patients who benefited seemed to have new, helpful bacteria from the donor take hold in their gut, and their blood showed signs of a more active immune system. They also identified specific patterns of gut bacteria linked to a better response to treatment. This is just a first step, but it shows that combining a gut bacteria transplant with immunotherapy is a safe and feasible path to explore for patients who have otherwise run out of effective treatments.
Could a gut bacteria transplant help when immunotherapy stops working for stomach cancer?
Photo by CDC / Unsplash
What this means for you:
Combining a gut bacteria transplant with immunotherapy was safe and showed early promise for some patients with resistant stomach cancer. More on Anti-PD-(L)1 refractory GI cancers
Phase III trial indicates ultra-low-dose nivolumab may improve survival over chemotherapy in advanced solid tumors A Tiny Dose of This Cancer Drug Is Outperforming Chemo
· Apr 23, 2026
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial New Combo Shows Modest Promise for Hard-to-Treat Neuroendocrine Cancers
· Apr 23, 2026
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis. 15,000 Cases Found: Which Drugs Harm Your Lungs?
Frontiers · Apr 22, 2026
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
Frontiers · Apr 21, 2026